FindTrial
Sign In

Study on reduced effectiveness of platelet transfusions in AML patients during initial chemotherapy

Platelet refractoriness in acute myeloid leukemia patients selected for intensive chemotherapy in the induction phase - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/04/108059
Enrollment
30
Registered
2026-04-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C920- Acute myeloblastic leukemia

Interventions

Intervention1: nil: nil Intervention2: Nil: Nil Control Intervention1: nil: nil

Sponsors

Jawaharlal Institute of Postgraduate Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: >/= 18yrs Both males and females Newly diagnosed AML patients selected for intensive chemotherapy in the induction phase

Exclusion criteria

Exclusion criteria: Recipients of multiple blood transfusions previously

Design outcomes

Primary

MeasureTime frame
To assess the prevalence and outcomes of platelet refractoriness among acute myeloid leukemia pa-tients receiving chemotherapy in the induction phaseTimepoint: To assess the prevalence and outcomes of platelet refractoriness among acute myeloid leukemia pa-tients receiving chemotherapy in the induction phase at baseline, 12 weeks and 24 weeks—

Secondary

MeasureTime frame
To assess the risk factors of platelet refractoriness among acute myeloid leukemia patients receiving chemotherapy in the induction phase. To identify the rate of Human leukocyte antigen (HLA) & Human platelet antigen (HPA) alloim-munization among these patients Timepoint: at baseline, 12 weeks & 24 weeks—

Countries

India

Contacts

Public ContactDr Aparna Krishna

JIPMER

aparnakrishna00@gmail.com9496840620

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026